Your browser doesn't support javascript.
loading
The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan.
Kaneko, Yudai; Sugiyama, Akira; Tanaka, Toshiya; Fukui, Kazushige; Taguchi, Akashi; Tatsuno, Kenji; Nakayama, Aya; Koga, Kazumasa; Kishi, Yoshiro; Daming, Wang; Qian, Chungen; Xia, Fuzhen; He, Fan; Zheng, Liang; Yu, Yi; Wada, Youichiro; Wada, Yoshiaki; Kodama, Tatsuhiko; Kawamura, Takeshi.
Afiliação
  • Kaneko Y; Research Center for Advanced Science and Technology (RCAST) The University of Tokyo Tokyo Japan.
  • Sugiyama A; Medical & Biological Laboratories Co. Ltd Tokyo Japan.
  • Tanaka T; Research Center for Advanced Science and Technology (RCAST) The University of Tokyo Tokyo Japan.
  • Fukui K; Isotope Science Center The University of Tokyo Tokyo Japan.
  • Taguchi A; Research Center for Advanced Science and Technology (RCAST) The University of Tokyo Tokyo Japan.
  • Tatsuno K; Isotope Science Center The University of Tokyo Tokyo Japan.
  • Nakayama A; Research Center for Advanced Science and Technology (RCAST) The University of Tokyo Tokyo Japan.
  • Koga K; Research Center for Advanced Science and Technology (RCAST) The University of Tokyo Tokyo Japan.
  • Kishi Y; Isotope Science Center The University of Tokyo Tokyo Japan.
  • Daming W; Department of Neurology Nissan Tamagawa Hospital Tokyo Japan.
  • Qian C; Medical & Biological Laboratories Co. Ltd Tokyo Japan.
  • Xia F; Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Suzhou China.
  • He F; Department of Biomedical Engineering, The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme College of Life Science and Technology, Huazhong University of Science and Tech
  • Zheng L; Reagent R&D Center Shenzhen YHLO Biotech Co. Ltd Guangdong China.
  • Yu Y; Reagent R&D Center Shenzhen YHLO Biotech Co. Ltd Guangdong China.
  • Wada Y; Reagent R&D Center Shenzhen YHLO Biotech Co. Ltd Guangdong China.
  • Wada Y; Reagent R&D Center Shenzhen YHLO Biotech Co. Ltd Guangdong China.
  • Kodama T; Research Center for Advanced Science and Technology (RCAST) The University of Tokyo Tokyo Japan.
  • Kawamura T; Isotope Science Center The University of Tokyo Tokyo Japan.
Health Sci Rep ; 5(3): e572, 2022 May.
Article em En | MEDLINE | ID: mdl-35509410
Background: We compared the temporal changes of immunoglobulin M (IgM), IgG, and IgA antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (N), spike 1 subunit (S1), and receptor-binding domain (RBD), and neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with coronavirus disease 2019 (COVID-19) to understand the humoral immunity in COVID-19 patients for developing drugs and vaccines for COVID-19. Methods: A total of five confirmed COVID-19 cases in Nissan Tamagawa Hospital in early August 2020 were recruited in this study. Using a fully automated chemiluminescence immunoassay analyzer, we measured the levels of IgG, IgA, and IgM against SARS-CoV-2 N, S1, and RBD and NAbs against SARS-CoV-2 in COVID-19 patients' sera acquired multiple times in individuals from 0 to 76 days after symptom onset. Results: IgG levels against SARS-CoV-2 structural proteins increased over time in all cases but IgM and IgA levels against SARS-CoV-2 showed different increasing trends among individuals in the early stage. In particular, we observed IgA increasing before IgG and IgM in some cases. The NAb levels were more than cut-off value in 4/5 COVID-19 patients some of whose antibodies against RBD did not exceed the cut-off value in the early stage. Furthermore, NAb levels against SARS-CoV-2 increased and kept above cut-off value more than around 70 days after symptom onset in all cases. Conclusion: Our findings indicate COVID-19 patients should be examined for IgG, IgA, and IgM against SARS-CoV-2 structural proteins and NAbs against SARS-CoV-2 to analyze the diversity of patients' immune mechanisms.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article